tiprankstipranks
Medtronic (MDT)
NYSE:MDT
US Market
Want to see MDT full AI Analyst Report?

Medtronic (MDT) Stock Forecast & Price Target

6,468 Followers
See the Price Targets and Ratings of:

MDT Analyst Ratings

Moderate Buy
22Ratings
Moderate Buy
13 Buy
9 Hold
0 Sell
Based on 22 analysts giving stock ratings to
Medtronic
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

MDT Stock 12 Month Forecast

Average Price Target

$106.35
▲(23.39% Upside)
Based on 22 Wall Street analysts offering 12 month price targets for Medtronic in the last 3 months. The average price target is $106.35 with a high forecast of $121.00 and a low forecast of $86.00. The average price target represents a 23.39% change from the last price of $86.19.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"79":"$79","122":"$122","89.75":"$89.8","100.5":"$100.5","111.25":"$111.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":121,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$121.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":106.35,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$106.35</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":86,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$86.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[79,89.75,100.5,111.25,122],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2025","6":"Oct<br/>2025","9":"Jan<br/>2026","12":"Apr<br/>2026","25":"Apr<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,86.06,88.7476923076923,91.43538461538462,94.12307692307692,96.81076923076924,99.49846153846154,102.18615384615384,104.87384615384616,107.56153846153846,110.24923076923076,112.93692307692308,115.62461538461538,118.31230769230768,{"y":121,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,86.06,87.62076923076923,89.18153846153847,90.74230769230769,92.30307692307693,93.86384615384615,95.42461538461538,96.98538461538462,98.54615384615384,100.10692307692307,101.6676923076923,103.22846153846153,104.78923076923077,{"y":106.35,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,86.06,86.05538461538461,86.05076923076923,86.04615384615384,86.04153846153847,86.03692307692307,86.0323076923077,86.0276923076923,86.02307692307693,86.01846153846154,86.01384615384616,86.00923076923077,86.00461538461539,{"y":86,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":85.764,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":80.986,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":81.16,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":86.73,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":87.307,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":90.698,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":93.355,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":89.308,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":101.754,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":95.282,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":101.878,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":97.305,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":86.06,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$121.00Average Price Target$106.35Lowest Price Target$86.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Jefferies
$95
Hold
10.22%
Upside
Assigned
04/24/26
Medtronic: Portfolio Streamlining and Diabetes Spin-Off Benefits Offset by Lower Growth Outlook and Valuation Compression, Justifying Hold Rating
UBS
$104$90
Hold
4.42%
Upside
Assigned
04/22/26
Medtronic price target lowered to $90 from $104 at UBSMedtronic price target lowered to $90 from $104 at UBS
Piper Sandler Analyst forecast on MDT
Piper Sandler
Piper Sandler
$91
Hold
5.58%
Upside
Reiterated
04/16/26
Analysts Offer Insights on Healthcare Companies: Medtronic (NYSE: MDT), Immunovant (NASDAQ: IMVT) and Biogen (NASDAQ: BIIB)
Truist Financial Analyst forecast on MDT
Truist Financial
Truist Financial
$103$95
Hold
10.22%
Upside
Reiterated
04/15/26
Medtronic price target lowered to $95 from $103 at TruistMedtronic price target lowered to $95 from $103 at Truist
Mizuho Securities Analyst forecast on MDT
Mizuho Securities
Mizuho Securities
$7$120
Buy
39.23%
Upside
Assigned
04/13/26
Medtronic price target lowered to $120 from $125 at MizuhoMedtronic price target lowered to $120 from $125 at Mizuho
RBC Capital
$118
Buy
36.91%
Upside
Reiterated
04/13/26
RBC Capital Sticks to Their Buy Rating for Medtronic (MDT)
Evercore ISI Analyst forecast on MDT
Evercore ISI
Evercore ISI
$108$106
Buy
22.98%
Upside
Assigned
04/09/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Staar Surgical (NASDAQ: STAA), Medtronic (NYSE: MDT) and Invivyd (NASDAQ: IVVD)
Stifel Nicolaus Analyst forecast on MDT
Stifel Nicolaus
Stifel Nicolaus
$95
Hold
10.22%
Upside
Reiterated
04/09/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Medtronic (NYSE: MDT) and Viridian Therapeutics (NASDAQ: VRDN)
Citi
$117$110
Buy
27.63%
Upside
Reiterated
04/07/26
Medtronic price target lowered to $110 from $117 at CitiMedtronic price target lowered to $110 from $117 at Citi
Argus Research Analyst forecast on MDT
Argus Research
Argus Research
$125$115
Buy
33.43%
Upside
Reiterated
04/06/26
Medtronic price target lowered to $115 from $125 at ArgusMedtronic price target lowered to $115 from $125 at Argus
Wells Fargo Analyst forecast on MDT
Wells Fargo
Wells Fargo
$114
Buy
32.27%
Upside
Assigned
04/02/26
Wells Fargo Reaffirms Their Buy Rating on Medtronic (MDT)
Barclays Analyst forecast on MDT
Barclays
Barclays
$118$120
Buy
39.23%
Upside
Reiterated
04/01/26
Analysts Offer Insights on Healthcare Companies: Medtronic (NYSE: MDT) and Apellis Pharmaceuticals (NASDAQ: APLS)
William Blair Analyst forecast on MDT
William Blair
William Blair
$86
Buy
-0.22%
Downside
Assigned
04/01/26
Analysts Offer Insights on Healthcare Companies: Scholar Rock Holding (NASDAQ: SRRK) and Medtronic (NYSE: MDT)
TD Cowen
$119
Buy
38.07%
Upside
Assigned
03/26/26
Analysts Offer Insights on Healthcare Companies: Amylyx Pharmaceuticals Inc (NASDAQ: AMLX), AbSci (NASDAQ: ABSI) and Medtronic (NYSE: MDT)
Needham
$120
Buy
39.23%
Upside
Assigned
03/26/26
Medtronic: Temporary MiniMed Charge Leaves Multi‑Year Earnings Growth and Buy Thesis Intact
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Jefferies
$95
Hold
10.22%
Upside
Assigned
04/24/26
Medtronic: Portfolio Streamlining and Diabetes Spin-Off Benefits Offset by Lower Growth Outlook and Valuation Compression, Justifying Hold Rating
UBS
$104$90
Hold
4.42%
Upside
Assigned
04/22/26
Medtronic price target lowered to $90 from $104 at UBSMedtronic price target lowered to $90 from $104 at UBS
Piper Sandler Analyst forecast on MDT
Piper Sandler
Piper Sandler
$91
Hold
5.58%
Upside
Reiterated
04/16/26
Analysts Offer Insights on Healthcare Companies: Medtronic (NYSE: MDT), Immunovant (NASDAQ: IMVT) and Biogen (NASDAQ: BIIB)
Truist Financial Analyst forecast on MDT
Truist Financial
Truist Financial
$103$95
Hold
10.22%
Upside
Reiterated
04/15/26
Medtronic price target lowered to $95 from $103 at TruistMedtronic price target lowered to $95 from $103 at Truist
Mizuho Securities Analyst forecast on MDT
Mizuho Securities
Mizuho Securities
$7$120
Buy
39.23%
Upside
Assigned
04/13/26
Medtronic price target lowered to $120 from $125 at MizuhoMedtronic price target lowered to $120 from $125 at Mizuho
RBC Capital
$118
Buy
36.91%
Upside
Reiterated
04/13/26
RBC Capital Sticks to Their Buy Rating for Medtronic (MDT)
Evercore ISI Analyst forecast on MDT
Evercore ISI
Evercore ISI
$108$106
Buy
22.98%
Upside
Assigned
04/09/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Staar Surgical (NASDAQ: STAA), Medtronic (NYSE: MDT) and Invivyd (NASDAQ: IVVD)
Stifel Nicolaus Analyst forecast on MDT
Stifel Nicolaus
Stifel Nicolaus
$95
Hold
10.22%
Upside
Reiterated
04/09/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Medtronic (NYSE: MDT) and Viridian Therapeutics (NASDAQ: VRDN)
Citi
$117$110
Buy
27.63%
Upside
Reiterated
04/07/26
Medtronic price target lowered to $110 from $117 at CitiMedtronic price target lowered to $110 from $117 at Citi
Argus Research Analyst forecast on MDT
Argus Research
Argus Research
$125$115
Buy
33.43%
Upside
Reiterated
04/06/26
Medtronic price target lowered to $115 from $125 at ArgusMedtronic price target lowered to $115 from $125 at Argus
Wells Fargo Analyst forecast on MDT
Wells Fargo
Wells Fargo
$114
Buy
32.27%
Upside
Assigned
04/02/26
Wells Fargo Reaffirms Their Buy Rating on Medtronic (MDT)
Barclays Analyst forecast on MDT
Barclays
Barclays
$118$120
Buy
39.23%
Upside
Reiterated
04/01/26
Analysts Offer Insights on Healthcare Companies: Medtronic (NYSE: MDT) and Apellis Pharmaceuticals (NASDAQ: APLS)
William Blair Analyst forecast on MDT
William Blair
William Blair
$86
Buy
-0.22%
Downside
Assigned
04/01/26
Analysts Offer Insights on Healthcare Companies: Scholar Rock Holding (NASDAQ: SRRK) and Medtronic (NYSE: MDT)
TD Cowen
$119
Buy
38.07%
Upside
Assigned
03/26/26
Analysts Offer Insights on Healthcare Companies: Amylyx Pharmaceuticals Inc (NASDAQ: AMLX), AbSci (NASDAQ: ABSI) and Medtronic (NYSE: MDT)
Needham
$120
Buy
39.23%
Upside
Assigned
03/26/26
Medtronic: Temporary MiniMed Charge Leaves Multi‑Year Earnings Growth and Buy Thesis Intact
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Medtronic

3 Months
xxx
Success Rate
17/24 ratings generated profit
71%
Average Return
+3.41%
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 70.83% of your transactions generating a profit, with an average return of +3.41% per trade.
1 Year
Matt MiksicBarclays
Success Rate
22/35 ratings generated profit
63%
Average Return
+5.63%
Copying Matt Miksic's trades and holding each position for 1 Year would result in 62.86% of your transactions generating a profit, with an average return of +5.63% per trade.
2 Years
xxx
Success Rate
16/24 ratings generated profit
67%
Average Return
+3.70%
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 66.67% of your transactions generating a profit, with an average return of +3.70% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

MDT Analyst Recommendation Trends

Rating
Dec 25
Jan 26
Feb 26
Mar 26
Apr 26
Strong Buy
0
0
0
0
0
Buy
34
27
30
33
35
Hold
23
21
20
14
18
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
57
48
50
47
53
In the current month, MDT has received 35 Buy Ratings, 18 Hold Ratings, and 0 Sell Ratings. MDT average Analyst price target in the past 3 months is 106.35.
Each month's total comprises the sum of three months' worth of ratings.

MDT Financial Forecast

MDT Earnings Forecast

Next quarter’s earnings estimate for MDT is $1.54 with a range of $1.52 to $1.56. The previous quarter’s EPS was $1.36. MDT beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year MDT has Performed in-line its overall industry.
Next quarter’s earnings estimate for MDT is $1.54 with a range of $1.52 to $1.56. The previous quarter’s EPS was $1.36. MDT beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year MDT has Performed in-line its overall industry.

MDT Sales Forecast

Next quarter’s sales forecast for MDT is $9.63B with a range of $9.18B to $9.71B. The previous quarter’s sales results were $9.02B. MDT beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year MDT has Performed in-line its overall industry.
Next quarter’s sales forecast for MDT is $9.63B with a range of $9.18B to $9.71B. The previous quarter’s sales results were $9.02B. MDT beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year MDT has Performed in-line its overall industry.

MDT Stock Forecast FAQ

What is MDT’s average 12-month price target, according to analysts?
Based on analyst ratings, Medtronic’s 12-month average price target is 106.35.
    What is MDT’s upside potential, based on the analysts’ average price target?
    Medtronic has 23.39% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is MDT a Buy, Sell or Hold?
          Medtronic has a consensus rating of Moderate Buy which is based on 13 buy ratings, 9 hold ratings and 0 sell ratings.
            What is Medtronic’s price target?
            The average price target for Medtronic is 106.35. This is based on 22 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $121.00 ,the lowest forecast is $86.00. The average price target represents 23.39% Increase from the current price of $86.19.
              What do analysts say about Medtronic?
              Medtronic’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 22 Wall Streets Analysts.
                How can I buy shares of MDT?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.